Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease
Vöglein, Jonathan , Morris, John C. , Dieterich, Marianne , Preische, Oliver, Hofmann, Anna, Hassenstab, Jason , Fagan, Anne M. , Noble, James M. , Berman, Sarah , Graff‐Radford, Neill R. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Salloway, Stephen , Xiong, Chengjie , Cairns, Nigel J., Perrin, Richard J. , Day, Gregory S. , Mori, Hiroshi , Suzuki, Kazushi , Masters, Colin L. , Goate, Alison , Buckles, Virginia, Fox, Nick C. , Chrem, Patricio, Ringman, John M. , Yakushev, Igor , Laske, Christoph , Bateman, Randall J. , Network, for the Dominantly Inherited Alzheimer, Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Franzmeier, Nicolai , McDade, Eric , Simons, Mikael , Benzinger, Tammie L.S. , Ghetti, Bernardino , Xiong, Chengjie , Karch, Celeste M. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Shimada, Hiroyuki , Ikeuchi, Takeshi , Schofield, Peter R. , Allegri, Ricardo , Jucker, Mathias , Höglinger, Günter U. , Danek, Adrian , Network, for the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | May 24, 2022 | Volume: 19 | Issue: 2 | Pages: 632-645

10.1002/alz.12684 | PMID 35609137 Get It

AbstractIntroductionAs knowledge about neurological examination findings in autosomal dominant Alzheimer disease (ADAD) is incomplete, we aimed to determine the frequency and significance of neurological examination findings in ADAD.MethodsFrequencies of neurological examination findings were compared between symptomatic mutation carriers and non mutation carriers from the Dominantly Inherited Alzheimer Network (DIAN) to define AD neurological examination findings. AD neurological examination findings were analyzed regarding frequency, association with and predictive value regarding cognitive decline, and association with brain atrophy in symptomatic mutation carriers.ResultsAD neurological examination findings included abnormal deep tendon reflexes, gait disturbance, pathological cranial nerve examination findings, tremor, abnormal finger to nose and heel to shin testing, and compromised motor strength. The frequency of AD neurological examination findings was 65.1%. Cross‐sectionally, mutation carriers with AD neurological examination findings showed a more than two‐fold faster cognitive decline and had greater parieto‐temporal atrophy, including hippocampal atrophy. Longitudinally, AD neurological examination findings predicted a significantly greater decline over time.DiscussionADAD features a distinct pattern of neurological examination findings that is useful to estimate prognosis and may inform clinical care and therapeutic trial designs.
Inflammatory myofibroblastic tumor: A multi‐institutional study from the Pediatric Surgical Oncology Research Collaborative
Rich, Barrie S. , Fishbein, Joanna , Lautz, Timothy B. , Rubalcava, Nathan S. , Kartal, Tanvi , Newman, Erika, Wok, Pei En, Romao, Rodrigo , Polites, Stephanie F. , Løfberg, Katrine , Lascano, Danny , Davidson, Jacob , Bütter, Andreana , Short, Scott S. , Meyers, Rebecka L. , Mastropolo, Rosemarie, Weller, Jennine , Irfan, Ahmer , Rhee, Daniel S. , Riehle, Kimberly J. , Tracy, Elisabeth T. , Becktell, Kerri, Hallis, Brian, Lal, Dave R. , Li, Orville, Dal‐Soglio, Dorothé B., Piché, Nelson , Quevedo, Oswaldo Gomez, Davidoff, Andrew M. , Barber, Jo Cooke, Watters, Erin, Dasgupta, Roshni , Glick, Richard D. , Lautz, Timothy , Tracy, Elisabeth T , Dasgupta, Roshni , Whitlock, Richard S. , Naik‐Mathuria, Bindi , Kim, Eugene S. , Kastenberg, Zachary J. , Malek, Marcus M. , Utria, Alan Fremder , Rothstein, David H. , Commander, Sarah Jane , Li, Orville, Dal-Soglio, Dorothée, Murphy, Andrew J. , Watters, Erin

Mayo Clinic

International Journal of Cancer | May 23, 2022 | Volume: 151 | Issue: 7 | Pages: 1059-1067

10.1002/ijc.34132 | PMID 35604778 Get It

Abstract Inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm of intermediate malignancy. We describe the largest cohort of IMT patients to date, aiming to further characterize this rare, poorly understood tumor. This is a multi‐institutional review of IMT patients ≤39 years, from 2000 to 2018, at 18 hospitals in the Pediatric Surgical Oncology Research Collaborative. One hundred and eighty‐two patients were identified with median age of 11 years. Thirty‐three percent of tumors were thoracic in origin. Presenting signs/symptoms included pain (29%), respiratory symptoms (25%) and constitutional symptoms (20%). Median tumor size was 3.9 cm. Anaplastic lymphoma kinase (ALK) overexpression was identified in 53% of patients. Seven percent of patients had distant disease at diagnosis. Ninety‐one percent of patients underwent resection: 14% received neoadjuvant treatment and 22% adjuvant treatment. Twelve percent of patients received an ALK inhibitor. Sixty‐six percent of surgical patients had complete resection, with 20% positive microscopic margins and 14% gross residual disease. Approximately 40% had en bloc resection of involved organs. Median follow‐up time was 36 months. Overall 5‐year survival was 95% and 5‐year event‐free survival was 80%. Predictors of recurrence included respiratory symptoms, tumor size and distant disease. Gross or microscopic margins were not associated with recurrence, suggesting that aggressive attempts at resection may not be warranted.
Muscle oxygenation during normoxic and hypoxic cycling exercise in humans with high‐affinity haemoglobin
Webb, Kevin, Elshaer, Ahmed , Dominelli, Paolo B. , Senefeld, Jonathon W. , Hammer, Shane M. , Baker, Sarah E. , Shepherd, John R.A. , Roy, Tuhin K. , Joyner, Michael J. , Wiggins, Chad C. , Elshaer, Ahmed N, Wiggins, Chad C , Joyner, Michael J , Senefeld, Jonathon W , Roy, Tuhin K , Baker, Sarah E , Webb, Kevin L.

Mayo Clinic

Experimental Physiology | May 23, 2022 | Volume: 107 | Issue: 8 | Pages: 854-863

10.1113/ep090308 | PMID 35603981 Get It

New Findings What is the central question of this study? Do humans with high‐affinity haemoglobin (HAH) demonstrate attenuated skeletal muscle deoxygenation during normoxic and hypoxic exercise? What is the main finding and its importance? Examination of near‐infrared spectroscopy‐derived muscle oxygenation profiles suggests that fractional oxygen extraction is blunted during hypoxic exercise in humans with HAH compared with control subjects. However, muscle tissue oxygen saturation levels were higher in humans with HAH during exercise in normoxia compared with control subjects. These alterations in fractional oxygen extraction in humans with HAH might influence blood flow regulation and exercise capacity during hypoxia. AbstractRecently, researchers in our laboratory have shown that humans with genetic mutations resulting in high‐affinity haemoglobin (HAH) demonstrate better maintained aerobic capacity and peak power output during hypoxic exercise versus normoxic exercise in comparison to humans with normal‐affinity haemoglobin. However, the influence of HAH on tissue oxygenation within exercising muscle during normoxia and hypoxia is unknown. Therefore, we examined near‐infrared spectroscopy‐derived oxygenation profiles of the vastus lateralis during graded cycling exercise in normoxia and hypoxia among humans with HAH (n = 5) and control subjects with normal‐affinity haemoglobin (n = 12). The HAH group elicited a blunted increase of deoxygenated haemoglobin + myoglobin during hypoxic exercise compared with the control group (P = 0.03), suggesting reduced fractional oxygen extraction in the HAH group. In addition, the HAH group maintained a higher level of muscle tissue oxygen saturation during normoxic exercise (HAH, 75 ± 4% vs. controls, 65 ± 3%, P = 0.049) and there were no differences between groups in muscle tissue oxygen saturation during hypoxic exercise (HAH, 68 ± 3% vs. controls, 68 ± 2%, P = 0.943). Overall, our results suggest that humans with HAH might demonstrate divergent patterns of fractional oxygen extraction during hypoxic exercise and elevated muscle tissue oxygenation during normoxic exercise compared with control subjects.
Sodium‐glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation
Lemke, Adley , Brokmeier, Hannah M., Leung, Sarah B., Mara, Kristin C. , Wadei, Hani M. , Hill, Jennifer M. , Stegall, Mark D. , Kudva, Yogish C. , Shah, Pankaj, Kukla, Aleksandra , Mour, Girish K., Stegall, Mark D , Kudva, Yogish C. , Kukla, Aleksandra , Mara, Kristin C , Lemke, Adley I , Wadei, Hani M , Mour, Girish , Shah, Pankaj

Mayo Clinic

Clinical Transplantation | May 20, 2022 | Volume: 36 | Issue: 8 | Pages: No page available

10.1111/ctr.14718 | PMID 35593882 Get It

Abstract Introduction Diabetes mellitus in kidney transplant recipients is a risk factor for cardiovascular events and premature death. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are increasingly used in nontransplant populations to improve diabetes control and cardiovascular and renal benefits. Limited literature exists regarding the safety and efficacy of these agents in renal transplant recipients. Methods We retrospectively reviewed all kidney transplant recipients within our health system who were prescribed a SGLT2i after transplantation for diabetes. The safety, tolerability, and effectiveness of SGLT2i were analyzed. Results Thirty‐nine kidney transplant recipients were initiated on SGLT2i therapy, twenty‐seven of which remained on therapy for at least 1 year. Ten (25%) patients experienced an adverse event while on a SGLT2i, with urinary tract infections (UTI) being the most common. Seventeen patients (43%) discontinued the SGLT2i at the time of chart review, most commonly due to cost and kidney function decline. The median [IQR] hemoglobin A1c (HbA1c) at SGLT2i initiation of 8.4% [7.8–9.2] decreased to 7.5% [6.8–8.0%] after 3 months and 7.5% [6.5–7.9] after 12 months. No meaningful change in kidney function or tacrolimus exposure was observed. Conclusion SGLT2i may be a safe and effective treatment for diabetes in kidney transplant recipients. Cost is a barrier to SGLT2i therapy, and UTIs were the most frequently encountered adverse events in this cohort. More studies are needed to understand the safety profile and determine the effect of SGLT2i on diabetes‐related comorbidities among kidney transplant recipients.
Performing parotidectomy postoperative follow-ups via telemedicine: Experience at a tertiary care, multiple-surgeon otolaryngology center
Antezana, Luis A. , Xie, Katherine , Bowen, Andrew J, Yeakel, Sarah, Nassiri, Ashley M. , Moore, Eric J. , Xie, Katherine Z , Antezana, Luis , Yin, Linda X. , Bowen, Andrew J

Mayo Clinic

Journal of Telemedicine and Telecare | May 18, 2022 | Volume: 30 | Issue: 4 | Pages: 739-746

10.1177/1357633x221095319 | PMID 35549759 Get It

Introduction We examined the suitability of using a video visit platform to perform postoperative parotidectomy evaluation at a tertiary care, multiple-surgeon otolaryngology center. Methods A retrospective case review was conducted of patients who underwent parotidectomy and postoperative video visits between November 2019 and December 2020. Success of video visit, plan if applicable, and post-visit outcomes were reviewed. Video visits were designated as successful if the physician could assess for complications in the postoperative course (e.g. first bite pain, Frey syndrome, ear numbness, unplanned visits to the emergency department, unplanned return to the operating room), perform examination of facial nerve function, and formulate care recommendations per clinical judgement without deferment of recommendations for a subsequent in-person visit. Results There were 96 postoperative video visits with 91 unique parotidectomy patients. Demographics: 28/63 male/female; average age, 54y. All video visits were suitable for successful postoperative parotidectomy patient evaluation. Eight visits (8.3%) consisted of patients presenting with common postoperative complications (e.g. eye dryness, first bite pain) and warranted care recommendations. In only two cases did the patient require further in-person procedural (hematoma evacuation, seroma aspiration) follow-ups. For the other 91.7% of visits (n = 88), no additional recommendations were required as patients experienced uncomplicated postoperative courses. Of all the patients, 26.1% (n = 23) were instructed to follow-up for routine surveillance. All other patients, 73.9% (n = 65) were instructed to follow-up as needed. Conclusion Postoperative parotidectomy evaluation is highly amenable to being performed by video. A telemedicine option offers convenience for patients in the majority of cases without compromising clinical assessment and judgment for the physician.
Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology
Schofield, Peter R. , Weiner, Michael W. , Xiong, Chengjie , Coble, Dean W. , Saito, Naomi , Aisen, Paul, Berman, Sarah , Cairns, Nigel J., Carrillo, María C. , Chui, Helena C., Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Graff‐Radford, Neill R. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Jagust, William J. , Massoumzadeh, Parinaz , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Petersen, Ronald C. , Ringman, John M. , Salloway, Stephen , Saykin, Andrew J. , Shaw, Leslie M. , Trojanowski, John Q. , Vöglein, Jonathan , Weninger, Stacie, Bateman, Randall J. , Buckles, Virginia, Morris, John C. , Schofield, Peter R , Gordon, Brian A , Ikeuchi, T , Jack, Clifford R , Jagust, William J , Masters, Colin L , Vöglein, Jonathan , Saykin, Andrew J , Day, Gregory S , Bateman, Randall J , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Xiong, Chengjie , Beckett, Laurel , Allegri, Ricardo , Benzinger, Tammie L.S. , Chui, Helena C. , Cruchaga, Carlos , Ghetti, Bernardino , Ikeuchi, Takeshi , Jucker, Mathias , Martins, Ralph N. , McDade, Eric , Toga, Arthur W.

Mayo Clinic

Brain | May 17, 2022 | Volume: 145 | Issue: 10 | Pages: 3594-3607

10.1093/brain/awac181 | PMID 35580594 Get It

AbstractThe extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the pathophysiology of ‘sporadic’ late onset Alzheimer's disease is unknown, thus limiting the extrapolation of study findings and clinical trial results in autosomal dominant Alzheimer's disease to late onset Alzheimer's disease.We compared brain MRI and amyloid PET data, as well as CSF concentrations of amyloid-β42, amyloid-β40, tau and tau phosphorylated at position 181, in 292 carriers of pathogenic variants for Alzheimer's disease from the Dominantly Inherited Alzheimer Network, with corresponding data from 559 participants from the Alzheimer’s Disease Neuroimaging Initiative. Imaging data and CSF samples were reprocessed as appropriate to guarantee uniform pipelines and assays. Data analyses yielded rates of change before and after symptomatic onset of Alzheimer's disease, allowing the alignment of the ∼30-year age difference between the cohorts on a clinically meaningful anchor point, namely the participant age at symptomatic onset.Biomarker profiles were similar for both autosomal dominant Alzheimer's disease and late onset Alzheimer's disease. Both groups demonstrated accelerated rates of decline in cognitive performance and in regional brain volume loss after symptomatic onset. Although amyloid burden accumulation as determined by PET was greater after symptomatic onset in autosomal dominant Alzheimer's disease than in late onset Alzheimer's disease participants, CSF assays of amyloid-β42, amyloid-β40, tau and p-tau181 were largely overlapping in both groups. Rates of change in cognitive performance and hippocampal volume loss after symptomatic onset were more aggressive for autosomal dominant Alzheimer's disease participants.These findings suggest a similar pathophysiology of autosomal dominant Alzheimer's disease and late onset Alzheimer's disease, supporting a shared pathobiological construct.
Functional validation of a novel AAAS variant in an atypical presentation of Allgrove syndrome
Macke, Erica L. , Morales‐Rosado, Joel A. , Macklin‐Mantia, Sarah K. , Schmitz, Christopher T., Oskarsson, Björn , Klee, Eric W. , Wierenga, Klaas J. , Oskarsson, Björn , Schmitz, Christopher , Morales-Rosado, Joel A

Mayo Clinic

Molecular Genetics & Genomic Medicine | May 16, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/mgg3.1966 | PMID 35570467 Get It

AbstractBackgroundAchalasia‐addisonianism‐alacrima syndrome, frequently referred to as Allgrove syndrome or Triple A syndrome, is a multisystem disorder resulting from homozygous or compound heterozygous pathogenic variants in the gene encoding aladin (AAAS). Aladin is a member of the WD‐repeat family of proteins and is a component of the nuclear pore complex. It is thought to be involved in nuclear import and export of molecules. Here, we describe an individual with a paternally inherited truncating variant and a maternally inherited, novel missense variant in AAAS presenting with alacrima, achalasia, anejaculation, optic atrophy, muscle weakness, dysarthria, and autonomic dysfunction.MethodsWhole‐exome sequencing was performed in the proband, sister, and parents. Variants were confirmed by Sanger sequencing. The localization of aladin to the nuclear pore was assessed in cells expressing the patient variant.ResultsFunctional testing of the maternally inherited variant, p.(Arg270Pro), demonstrated decreased localization of aladin to the nuclear pore in cells expressing the variant, indicating a deleterious effect. Follow‐up testing in the proband's affected sister revealed that she also inherited the biallelic AAAS variants.ConclusionsReview of the patient's clinical, pathological, and genetic findings resulted in a diagnosis of Triple A syndrome.
Contribution of Verbal Learning & Memory and Spectro‐Temporal Discrimination to Speech Recognition in Cochlear Implant Users
Harris, Michael S. , Hamel, Benjamin , Wichert, Kristin, Kozlowski, Kristin, Mleziva, Sarah, Ray, Christin , Pisoni, David B. , Moberly, Aaron C. , Hamel, Benjamin L, Moberly, Aaron C , Harris, Michael S , Kronenberger, William G.

Mayo Clinic

The Laryngoscope | May 14, 2022 | Volume: 133 | Issue: 3 | Pages: 661-669

10.1002/lary.30210 | PMID 35567421 Get It

ObjectivesExisting cochlear implant (CI) outcomes research demonstrates a high degree of variability in device effectiveness among experienced CI users. Increasing evidence suggests that verbal learning and memory (VL&M) may have an influence on speech recognition with CIs. This study examined the relations in CI users between visual measures of VL&M and speech recognition in a series of models that also incorporated spectro‐temporal discrimination. Predictions were that (1) speech recognition would be associated with VL&M abilities and (2) VL&M would contribute to speech recognition outcomes above and beyond spectro‐temporal discrimination in multivariable models of speech recognition.MethodsThis cross‐sectional study included 30 adult postlingually deaf experienced CI users who completed a nonauditory visual version of the California Verbal Learning Test‐Second Edition (v‐CVLT‐II) to assess VL&M, and the Spectral‐Temporally Modulated Ripple Test (SMRT), an auditory measure of spectro‐temporal processing. Participants also completed a battery of word and sentence recognition tasks.ResultsCI users showed significant correlations between some v‐CVLT‐II measures (short‐delay free‐ and cued‐recall, retroactive interference, and “subjective” organizational recall strategies) and speech recognition measures. Performance on the SMRT was correlated with all speech recognition measures. Hierarchical multivariable linear regression analyses showed that SMRT performance accounted for a significant degree of speech recognition outcome variance. Moreover, for all speech recognition measures, VL&M scores contributed independently in addition to SMRT.ConclusionMeasures of spectro‐temporal discrimination and VL&M were associated with speech recognition in CI users. After accounting for spectro‐temporal discrimination, VL&M contributed independently to performance on measures of speech recognition for words and sentences produced by single and multiple talkers.Level of Evidence3 Laryngoscope, 133:661–669, 2023
Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4
Pinsker, Jordan E. , Dassau, Eyal , Deshpande, Sunil , Raghinaru, Dan, Buckingham, Bruce A. , Kudva, Yogish C. , Laffel, Lori M. , Church, Mei Mei , Desrochers, Hannah, Ekhlaspour, Laya , Kaur, Ravinder Jeet , Levister, Camilla, Lum, John W. , Kollman, Craig, Ambler-Osborn, Louise, Freiner, Emily , O’Malley, Grenye , Brooks, Danielle , Ogyaadu, Selassie, Plesser, Mitchell, Simha, Vinaya , Desjardins, Donna, McCrady-Spitzer, Shelly , Nolander, Lisa, Hsu, Liana, Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Ekhlaspour, Laya , Lum, John , Doyle, Francis J , Buckingham, Bruce , Levy, Carol J. , Shi, Dawei , Kollman, Craig , Doyle, Francis J. , Isganaitis, Elvira , Beck, Roy W. , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | May 12, 2022 | Volume: 24 | Issue: 9 | Pages: 635-642

10.1089/dia.2022.0084 | PMID 35549708 Get It

Background: Automated insulin delivery (AID) systems have proven effective in increasing time-in-range during both clinical trials and real-world use. Further improvements in outcomes for single-hormone (insulin only) AID may be limited by suboptimal insulin delivery settings. Methods: Adults (≥18 years of age) with type 1 diabetes were randomized to either sensor-augmented pump (SAP) (inclusive of predictive low-glucose suspend) or adaptive zone model predictive control AID for 13 weeks, then crossed over to the other arm. Each week, the AID insulin delivery settings were sequentially and automatically updated by an adaptation system running on the study phone. Primary outcome was sensor glucose time-in-range 70–180 mg/dL, with noninferiority in percent time below 54 mg/dL as a hierarchical outcome. Results: Thirty-five participants completed the trial (mean age 39 ± 16 years, HbA1c at enrollment 6.9% ± 1.0%). Mean time-in-range 70–180 mg/dL was 66% with SAP versus 69% with AID (mean adjusted difference +2% [95% confidence interval: −1% to +6%], P = 0.22). Median time <70 mg/dL improved from 3.0% with SAP to 1.6% with AID (−1.5% [−2.4% to −0.5%], P = 0.002). The adaptation system decreased initial basal rates by a median of 4% (−8%, 16%) and increased initial carbohydrate ratios by a median of 45% (32%, 59%) after 13 weeks. Conclusions: Automated adaptation of insulin delivery settings with AID use did not significantly improve time-in-range in this very well-controlled population. Additional study and further refinement of the adaptation system are needed, especially in populations with differing degrees of baseline glycemic control, who may show larger benefits from adaptation.